Notably, inactivation of the 53BP1-dependent resection barrier dramatically reduces the effectiveness of the treatment on BRCA1 defective cells, possibly leading to genome instability, poor prognosis, and cancer relapse (Lord and Ashworth, 2017; Setiaputra and Durocher, 2019). This evidence concerns the gene TP53BP1 and cancer.